Merck takes Terns
After reporting stellar data at ASH, Terns is acquired for $6.7bn.
Like Lilly, Novartis bets against mutation specificity
The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
BioNTech plans a spin-off
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
Servier makes a rare big buy
The company pays $2.5bn for Day One and its approved drug Ojemda.
Gyre picks up Cullgen for its degraders
Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
Kairos expands lung resistance strategy
The company will license EGFR and cMet inhibitors from Celyn.
Vir tempts Astellas
The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
